Zum Inhalt springen
Home » HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

HepaRegenix, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, today announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and…

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration
LabNews Media LLC

LabNews Media LLC

The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu